Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Panic disorder can be treated with pharmacotherapy, psychotherapy or in combination, but the relative merits of combined therapy have not been well established. OBJECTIVES: To review evidence concerning short- and long-term advantages and disadvantages of combined psychotherapy plus antidepressant treatment for panic disorder with or without agoraphobia, in comparison with either therapy alone. SEARCH STRATEGY: The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (CCDANCTR-Studies and CCDANCTR-References) were searched on 11/10/2005, together with a complementary search of the Cochrane Central Register of Controlled Trials and MEDLINE, using the keywords antidepressant and panic. A reference search, SciSearch and personal contact with experts were carried out. SELECTION CRITERIA: Two independent review authors identified randomised controlled trials comparing the combined therapy against either of the monotherapies among adult patients with panic disorder with or without agoraphobia. DATA COLLECTION AND ANALYSIS: Two independent review authors extracted data using predefined data formats, including study quality indicators. The primary outcome was relative risk (RR) of "response" i.e. substantial overall improvement from baseline as defined by the original investigators. Secondary outcomes included standardised weighted mean differences in global severity, panic attack frequency, phobic avoidance, general anxiety, depression and social functioning and relative risks of overall dropouts and dropouts due to side effects. MAIN RESULTS: We identified 23 randomised comparisons (representing 21 trials, 1709 patients), 21 of which involved behaviour or cognitive-behaviour therapies. In the acute phase treatment, the combined therapy was superior to antidepressant pharmacotherapy (RR 1.24, 95% confidence interval (CI) 1.02 to 1.52) or psychotherapy (RR 1.17, 95% CI 1.05 to 1.31). The combined therapy produced more dropouts due to side effects than psychotherapy (number needed to harm (NNH) around 26). After the acute phase treatment, as long as the drug was continued, the superiority of the combination over either monotherapy appeared to persist. After termination of the acute phase and continuation treatment, the combined therapy was more effective than pharmacotherapy alone (RR 1.61, 95% CI 1.23 to 2.11) and was as effective as psychotherapy (RR 0.96, 95% CI 0.79 to 1.16). AUTHORS' CONCLUSIONS: Either combined therapy or psychotherapy alone may be chosen as first line treatment for panic disorder with or without agoraphobia, depending on patient preference.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Imputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568
Self-citationEgger, M., Jüni, P., Bartlett, C., Holenstein, F., & Sterne, J. (2003) · Health Technology Assessment · doi:10.3310/hta7010 · Cited by 1,181
Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000) · JAMA · doi:10.1001/jama.283.19.2529 · Cited by 953
A consumer's guide to subgroup analyses
Oxman, A. D., & Guyatt, G. H. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-1-78 · Cited by 914
Marshall, M., Lockwood, A., Bradley, C., Adams, C., Joy, C., & Fenton, M. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.3.249 · Cited by 870
Bias in treatment assignment in controlled clinical trials
Chalmers, T. C., Celano, P., Sacks, H. S., & Smith, H. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312013092204 · Cited by 864
Kessler, R. C., Chiu, W. T., Jin, R., Ruscio, A. M., Shear, K., & Walters, E. E. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.4.415 · Cited by 795
A meta-analysis of treatment outcome for panic disorder
Gould, R. A., Ott, M. W., & Pollack, M. H. (1995) · Clinical Psychology Review · doi:10.1016/0272-7358(95)00048-8 · Cited by 520
Research works printed but not linked: 119
- Azhar, 2000, Comparison of fluvoxamine alone, fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan--implications for management by family doctors, Medical Journal of Malaysia, 55, 402
- Gorman, 2003, The effect of pharmacotherapist characteristics on treatment outcome in panic disorder, Depression and Anxiety, 17, 88, 10.1002/da.10087 · DOI
- Grilo, 1998, Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder, Comprehensive Psychiatry, 39, 323, 10.1016/S0010-440X(98)90043-8 · DOI · Paper page
- Hofmann, 1998, Effects of panic disorder treatments on personality disorder characteristics, Depression and Anxiety, 8, 14, 10.1002/(SICI)1520-6394(1998)8:1<14::AID-DA3>3.0.CO;2-5 · DOI
- Barlow, 2000, Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial, JAMA, 283, 2529, 10.1001/jama.283.19.2529 · DOI · Paper page
- Gorman, 2003, The effect of pharmacotherapist characteristics on treatment outcome in panic disorder, Depression and Anxiety, 17, 88, 10.1002/da.10087 · DOI
- Grilo, 1998, Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder, Comprrehensive Psychiatry, 39, 323, 10.1016/S0010-440X(98)90043-8 · DOI · Paper page
- Hofmann, 1998, Pretreatment attrition in a comparative treatment outcome study on panic disorder, American Journal of Psychiatry, 155, 43, 10.1176/ajp.155.1.43 · DOI · Paper page
- Hofmann, 1998, Effects of panic disorder treatments on personality disorder characteristics, Depression and Anxiety, 8, 14, 10.1002/(SICI)1520-6394(1998)8:1<14::AID-DA3>3.0.CO;2-5 · DOI
- Huppert, 2001, Therapists, therapist variables, and cognitive-behavioral therapy outcome in a multicenter trial for panic disorder, Journal of Consulting and Clinical Psychology, 69, 747, 10.1037/0022-006X.69.5.747 · DOI · Paper page
- Barlow, 2000, Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial, JAMA, 283, 2529, 10.1001/jama.283.19.2529 · DOI · Paper page
- Gorman, 2003, The effect of pharmacotherapist characteristics on treatment outcome in panic disorder, Depression and Anxiety, 17, 88, 10.1002/da.10087 · DOI
- Grilo, 1998, Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder, Comprehensive Psychiatry, 39, 323, 10.1016/S0010-440X(98)90043-8 · DOI · Paper page
- Hofmann, 1998, Pretreatment attrition in a comparative treatment outcome study on panic disorder, American Journal of Psychiatry, 155, 43, 10.1176/ajp.155.1.43 · DOI · Paper page
- Hofmann, 1998, Effects of panic disorder treatments on personality disorder characteristics, Depression and Anxiety, 8, 14, 10.1002/(SICI)1520-6394(1998)8:1<14::AID-DA3>3.0.CO;2-5 · DOI
- Huppert, 2001, Therapists, therapist variables, and cognitive-behavioral therapy outcome in a multicenter trial for panic disorder, Journal of Consulting and Clinical Psychology, 69, 747, 10.1037/0022-006X.69.5.747 · DOI · Paper page
- Berger, 2004, Personality disorder and social anxiety predict delayed response in drug and behavioral treatment of panic disorder, Journal of Affective Disorders, 80, 75, 10.1016/S0165-0327(03)00043-0 · DOI
- Beurs, 1999, Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up, Acta Psychiatrica Scandinavica, 99, 59, 10.1111/j.1600-0447.1999.tb05385.x · DOI · Paper page
- Beurs, 1995, Perceived upbringing and its relation to treatment outcome in agoraphobia, Clinical Psychology and Psychotherapy, 2, 78, 10.1002/cpp.5640020203 · DOI
- Balkom, 1996, Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia, Journal of Nervous and Mental Disease, 184, 133, 10.1097/00005053-199602000-00015 · DOI
- van Balkom AJ de Beurs E van Dyck R Lange A Two-year follow-up after treatment of panic disorder with agoraphobia. 8th European College of Neuropsychopharmacology Congress 8th European College of Neuropsychopharmacology Congress 1995 · doi:10.1016/0924-977x(96)87819-9
- Beurs, 1995, Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone, American Journal of Psychiatry, 152, 683, 10.1176/ajp.152.5.683 · DOI · Paper page
- Beurs, 1999, Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up, Acta Psychiatrica Scandinavica, 99, 59, 10.1111/j.1600-0447.1999.tb05385.x · DOI · Paper page
- Beurs, 1995, Perceived upbringing and its relation to treatment outcome in agoraphobia, Clinical Psychology and Psychotherapy, 2, 78, 10.1002/cpp.5640020203 · DOI
- Balkom, 1996, Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia, Journal of Nervous and Mental Disease, 184, 133, 10.1097/00005053-199602000-00015 · DOI
- van Balkom AJ de Beurs E van Dyck R Lange A Two-year follow-up after treatment of panic disorder with agoraphobia. 8th European College of Neuropsychopharmacology Congress 8th European College of Neuropsychopharmacology Congress 1995 · doi:10.1016/0924-977x(96)87819-9
- Beurs, 1995, Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone, American Journal of Psychiatry, 152, 683, 10.1176/ajp.152.5.683 · DOI · Paper page
- Beurs, 1999, Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up, Acta Psychiatrica Scandinavica, 99, 59, 10.1111/j.1600-0447.1999.tb05385.x · DOI · Paper page
- Beurs, 1995, Perceived upbringing and its relation to treatment outcome in agoraphobia, Clinical Psychology and Psychotherapy, 2, 78, 10.1002/cpp.5640020203 · DOI
- Balkom, 1996, Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia, Journal of Nervous and Mental Disease, 184, 133, 10.1097/00005053-199602000-00015 · DOI
- van Balkom AJ de Beurs E van Dyck R Lange A Two-year follow-up after treatment of panic disorder with agoraphobia. 8th European College of Neuropsychopharmacology Congress 8th European College of Neuropsychopharmacology Congress 1995 · doi:10.1016/0924-977x(96)87819-9
- Fahy, 1992, The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial, Journal of Affective Disorders, 25, 63, 10.1016/0165-0327(92)90094-M · DOI
- O'Rourke, 1996, The Galway study of panic disorder III: Outcome at 5 to 6 years, British Journal of Psychiatry, 168, 462, 10.1192/bjp.168.4.462 · DOI · Paper page
- Johnson, 1995, Clomipramine therapy and behavior therapy with agoraphobic women, Canadian Journal of Psychiatry - Revue Canadienne De Psychiatrie, 40, 192
- Loerch, 1999, Randomised placebo-controlled trial of moclobemide, cognitive- behavioural therapy and their combination in panic disorder with agoraphobia, British Journal of Psychiatry, 174, 205, 10.1192/bjp.174.3.205 · DOI · Paper page
- Cohen, 1984, Two-year follow-up of agoraphobics after exposure and imipramine, British Journal of Psychiatry, 144, 276, 10.1192/bjp.144.3.276 · DOI · Paper page
- Lelliott, 1987, Agoraphobics 5 years after imipramine and exposure. Outcome and predictors, Journal of Nervous and Mental Disease, 175, 599, 10.1097/00005053-198710000-00004 · DOI · Paper page
- Marks, 1983, Imipramine and brief therapists-aided exposure in agoraphobics having self-exposure homework, Archives of General Psychiatry, 40, 153, 10.1001/archpsyc.1983.01790020047004 · DOI · Paper page
- Mavissakalian, 1983, Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice, British Journal of Psychiatry, 143, 348, 10.1192/bjp.143.4.348 · DOI · Paper page
- Mavissakalian, 1993, Combined behavioral-therapy and pharmacotherapy of agoraphobia, Journal of Psychiatric Research, 27, 179, 10.1016/0022-3956(93)90027-Y · doi:10.1016/0022-3956(93)90027-y
- Mavissakalian, 1982, Agoraphobia: behavioral and pharmacological treatments, preliminary outcome, and process findings, Psychopharmacology Bulletin, 18, 91
- Mavissakalian, 1986, Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine, Journal of Clinical Psychiatry, 47, 117
- Mavissakalian, 1983, Self-directed in vivo exposure practice in behavioral and pharmacological treatments of agoraphobia, Behavior Therapy, 14, 506, 10.1016/S0005-7894(83)80074-4 · DOI
- Mavissakalian, 1986, Two-year follow-up of exposure and imipramine treatment of agoraphobia, American Journal of Psychiatry, 143, 1106, 10.1176/ajp.143.9.1106 · DOI · Paper page
- Mavissakalian, 1985, Imipramine in the treatment of agoraphobia: dose-response relationships, American Journal of Psychiatry, 142, 1032, 10.1176/ajp.142.9.1032 · DOI
- Mavissakalian, 1993, Combined behavioral-therapy and pharmacotherapy of agoraphobia, Journal of Psychiatric Research, 27, 179, 10.1016/0022-3956(93)90027-Y · doi:10.1016/0022-3956(93)90027-y
- Mavissakalian, 1982, Agoraphobia: behavioral and pharmacological treatments, preliminary outcome, and process findings, Psychopharmacology Bulletin, 18, 91
- Mavissakalian, 1986, Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine, Journal of Clinial Psychiatry, 47, 117
- Mavissakalian, 1983, Self-directed in vivo exposure practice in behavioral and pharmacological treatments of agoraphobia, Behavior Therapy, 14, 506, 10.1016/S0005-7894(83)80074-4 · DOI
- Mavissakalian, 1986, Two-year follow-up of exposure and imipramine treatment of agoraphobia, American Journal of Psychiatry, 143, 1106, 10.1176/ajp.143.9.1106 · DOI · Paper page
- Mavissakalian, 1985, Imipramine in the treatment of agoraphobia: dose-response relationships, American Journal of Psychiatry, 142, 1032, 10.1176/ajp.142.9.1032 · DOI
- Sharp, 1999, Predicting treatment outcome for panic disorder and agoraphobia in primary care, Clinical Psychology and Psychotherapy, 6, 336, 10.1002/(SICI)1099-0879(199911)6:5<336::AID-CPP205>3.0.CO;2-H · DOI
- Sharp, 1998, Psychologist, patient, and general practitioneer ratings of outcome of pharmacological and psychological treatments for panic disorder and agoraphobia in primary care, Behavioural and Cognitive Psychotherapy, 26, 13, 10.1017/S1352465898000034 · DOI
- Sharp, 1997, Treatment-outcome research in panic disorder: Dilemmas in reconciling the demands of pharmacological and psychological methodologies, Journal of Psychopharmacology, 11, 373, 10.1177/026988119701100415 · DOI
- Sharp, 1997, Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care, British Journal of General Practice, 47, 150
- Sharp, 1996, Fluvoxamine, placebo and cognitive behaviour therapy used alone and in combination in the treatment of ppanic disorder and agoraphobia, Journal of Anxiety Disorders, 10, 219, 10.1016/0887-6185(96)00008-4 · DOI
- Sharp, 1999, Predicting treatment outcome for panic disorder and agoraphobia in primary care, Clinical Psychology and Psychotherapy, 6, 336, 10.1002/(SICI)1099-0879(199911)6:5<336::AID-CPP205>3.0.CO;2-H · DOI
- Sharp, 1998, Psychologist, patient, and general practitioneer ratings of outcome of pharmacological and psychological treatments for panic disorder and agoraphobia in primary care, Behavioural and Cognitive Psychotherapy, 26, 13, 10.1017/S1352465898000034 · DOI
- Sharp, 1997, Treatment-outcome research in panic disorder: Dilemmas in reconciling the demands of pharmacological and psychological methodologies, Journal of Psychopharmacology, 11, 373, 10.1177/026988119701100415 · DOI
- Sharp, 1997, Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care, British Journal of General Practice, 47, 150
- Sharp, 1996, Fluvoxamine, placebo and cognitive behaviour therapy used alone and in combination in the treatment of ppanic disorder and agoraphobia, Journal of Anxiety Disorders, 10, 219, 10.1016/0887-6185(96)00008-4 · DOI
- Sharp, 1999, Predicting treatment outcome for panic disorder and agoraphobia in primary care, Clinical Psychology and Psychotherapy, 6, 336, 10.1002/(SICI)1099-0879(199911)6:5<336::AID-CPP205>3.0.CO;2-H · DOI
- Sharp, 1998, Psychologist, patient, and general practitioneer ratings of outcome of pharmacological and psychological treatments for panic disorder and agoraphobia in primary care, Behavioural and Cognitive Psychotherapy, 26, 13, 10.1017/S1352465898000034 · DOI
- Sharp, 1997, Treatment-outcome research in panic disorder: Dilemmas in reconciling the demands of pharmacological and psychological methodologies, Journal of Psychopharmacology, 11, 373, 10.1177/026988119701100415 · DOI
- Sharp, 1997, Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care, British Journal of General Practice, 47, 150
- Sharp, 1996, Fluvoxamine, placebo and cognitive behaviour therapy used alone and in combination in the treatment of ppanic disorder and agoraphobia, Journal of Anxiety Disorders, 10, 219, 10.1016/0887-6185(96)00008-4 · DOI
- Sheehan, 1980, Treatment of endogenous anxiety with phobic, hysterical, and hypochondriachal symptoms, Archives of General Psychiatry, 37, 51, 10.1001/archpsyc.1980.01780140053006 · DOI · Paper page
- Sheehan, 1980, Treatment of endogenous anxiety with phobic, hysterical, and hypochondriachal symptoms, Archives of General Psychiatry, 37, 51, 10.1001/archpsyc.1980.01780140053006 · DOI · Paper page
- Spinhoven, 1996, Panic management, trazodone and a combination of both in the treatment of panic disorder, Clinical Psychology and Psychotherapy, 3, 86, 10.1002/(SICI)1099-0879(199606)3:2<86::AID-CPP91>3.0.CO;2-3 · DOI
- Stein, 2000, Do selective serotonin re-uptake inhibitors enhance the efficacy of very brief cognitive behavioral therapy for panic disorder? A pilot study, Psychiatry Research, 94, 191, 10.1016/S0165-1781(00)00154-2 · DOI
- Roth, 1988, Autonomic changes after treatment of agoraphobia with panic attacks, Psychiatry Research, 24, 95, 10.1016/0165-1781(88)90145-X · DOI
- Telch, 1985, Combined pharmacological and behavioral treatment for agoraphobia, Behavior Research and Therapy, 23, 325, 10.1016/0005-7967(85)90011-7 · DOI · Paper page
- Dahl AA Wiborg IM Pharmacotherapy and brief dynamic psychotherapy of panic disorder 9th European College of Neuropsychopharmacology Congress Amsterdam, The Netherlands 1996 · doi:10.1016/0924-977x(96)83138-5
- Wiborg, 1996, Does brief dynamic psychotherapy reduce the relapse rate of panic disorder?, Archives of General Psychiatry, 53, 689, 10.1001/archpsyc.1996.01830080041008 · DOI · Paper page
- Zitrin, 1983, Differential treatment of phobias: Use of imipramine for panic attacks, Journal of Behavior Therapy and Experimental Psychiatry, 14, 11, 10.1016/0005-7916(83)90006-X · DOI
- Zitrin, 1980, Treatment of agoraphobia with group exposure in vivo and imipramine, Archives of General Psychiatry, 37, 63, 10.1001/archpsyc.1980.01780140065007 · DOI · Paper page
- Klein, 1987, Panic and avoidance in agoraphobia. Application of path analysis to treatment studies, Archives of General Psychiatry, 44, 377, 10.1001/archpsyc.1987.01800160093011 · DOI · Paper page
- Klein, 1983, Treatment of phobias. II. Behavior therapy and supportive psychotherapy: are there any specific ingredients?, Archives of General Psychiatry, 40, 139, 10.1001/archpsyc.1983.01790020033003 · DOI · Paper page
- Lipsitz, 1999, Specific phobia 10-16 years after treatment, Depression and Anxiety, 10, 105, 10.1002/(SICI)1520-6394(1999)10:3<105::AID-DA3>3.0.CO;2-X · doi:10.1002/(sici)1520-6394(1999)10:3<105::aid-da3>3.0.co;2-x
- Zitrin, 1983, Differential treatment of phobias: Use of imipramine for panic attacks, Journal of Behavior Therapy and Experimental Psychiatry, 14, 11, 10.1016/0005-7916(83)90006-X · DOI
- Zitrin, 1976, Comparison of short-term treatment regimens in phobic patients: a preliminary report, 233
- Zitrin, 1978, Behavior therapy, supportive psychotherapy, imipramine, and phobias, Archives of General Psychiatry, 35, 307, 10.1001/archpsyc.1978.01770270057005 · DOI · Paper page
- Zitrin, 1983, Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo, Archives of General Psychiatry, 40, 125, 10.1001/archpsyc.1983.01790020019002 · DOI · Paper page
- Zitrin, 1981, Differentiation of panic anxiety from anticipatory anxiety and avoidance behavior
- Vigano C Bielli A Carozzi A Divino T Pagliarulo E Ba G Panic disorder: A two-year follow-up of an integrated treatment approach. Italian Journal of Psychopathology
- Chambless, 1982, Exposure and communications training in the treatment of agoraphobia, Behavior Research and Therapy, 20, 219, 10.1016/0005-7967(82)90140-1 · DOI
- Chambless, 1979, Flooding with Brevital in the treatment of agoraphobia: countereffective?, Behavior Research and Therapy, 17, 243, 10.1016/0005-7967(79)90039-1 · DOI
- Cox, 1988, Different rates of improvement of different symptoms in combined pharmacological and behavioral treatment of agoraphobia, Journal of Behavior Therapy and Experimental Psychiatry, 19, 119, 10.1016/0005-7916(88)90025-0 · DOI
- Lipsedge, 1973, The management of severe agoraphobia: a comparison of ipronizaid and systematic desensitization, Psychopharmacologia, 32, 67, 10.1007/BF00421708 · doi:10.1007/bf00421708
- Solyom, 1981, Phenelzine and exposure in the treatment of phobias, Biological Psychiatry, 16, 239
- American Psychiatric Association, 1998, Practice guideline for the treatment of patients with panic disorder, American Journal of Psychiatry, 155 Supplement, 1
- Bucher, 1997, The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials, Journal of Clinical Epidemiology, 50, 683, 10.1016/S0895-4356(97)00049-8 · DOI · Paper page
- Burns, 1986, Agoraphobia 8 years after behavioral treatment: a follow-up study with interview, self-report, and behavioral data, Behavior Therapy, 17, 580, 10.1016/S0005-7894(86)80096-X · DOI
- Carlbring, 2002, 12-month prevalence of panic disorder with or without agoraphobia in the Swedish general population, Social Psychiatry and Psychiatric Epidemiology, 37, 207, 10.1007/s00127-002-0542-y · DOI
- Calrk, 1990, Surreptitious drug use by patients in a panic disorder study, American Journal of Psychiatry, 147, 507, 10.1176/ajp.147.4.507 · DOI · Paper page
- Clum, 1993, A meta-analysis of treatments for panic disorder, Journal of Consulting and Clinical Psychology, 61, 317, 10.1037/0022-006X.61.2.317 · DOI · Paper page
- Coldiz, 1989, How study design affects outcomes in comparisons of therapy. I: medical, Statistics in Medicine, 9, 441, 10.1002/sim.4780080408 · DOI · Paper page
- Goisman, 1995, DSM-IV and the disappearnace of agoraphobia without history of panic disorder: new data on a controversial diagnosis, American Journal of Psychiatry, 152, 1438, 10.1176/ajp.152.10.1438 · DOI · Paper page
- Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
- Hollon, 1981, Placebo-psychotherapy combinations: inappropriate representations of psychotherapy in drug-psychotherapy comparative trials, Psychological Bulletin, 90, 467, 10.1037/0033-2909.90.3.467 · DOI
- Klein, 2000, Flawed meta-analyses comparing psychotherapy with pharmacotherapy, American Journal of Psychiatry, 157, 1204, 10.1176/appi.ajp.157.8.1204 · DOI · Paper page
- Mattick, 1990, Treatment of panic and agoraphobia: an integrative review, Journal of Nervous and Mental Disease, 178, 567, 10.1097/00005053-199009000-00003 · DOI · Paper page
- Mavissakalian, 1993, Combined behavioral therapy and pharmacotherapy of agoraphobia, Journal of Psychiatric Research, 27 Suppl 1, 179, 10.1016/0022-3956(93)90027-Y · doi:10.1016/0022-3956(93)90027-y
- Mavissakalian, 2002, Duration of imipramine therapy and relapse in panic disorder with agoraphobia, Journal of Clinical Psychopharmacology, 22, 294, 10.1097/00004714-200206000-00010 · DOI · Paper page
- Nathan, 2002, A Guide to Treatments that Work
- Otto, 1996, Maintenance of remission following cognitive behavior therapy for panic disorder: possible deleterious effects of concurrent medication treatment, Behavior Therapy, 27, 473, 10.1016/S0005-7894(96)80028-1 · DOI
- Otto, 2000, Empirically supported treatments for panic disorder: costs, benefits, and stepped care, Journal of Consulting and Clinical Psychology, 68, 556, 10.1037/0022-006X.68.4.556 · doi:10.1037/0022-006x.68.4.556 · Paper page
- Pollack, 2003, WCA recommendations for the long-term treatment of panic disorder, CNS Spectrums, 8, 17, 10.1017/S109285290000691X · DOI · Paper page
- Schmidt, 1999, Panic disorder: cognitive behavioral and pharmacological treatment strategies, Journal of Clinical Psychology in Medical Settings, 6, 89, 10.1023/A:1026207414971 · DOI
- Schmidt, 2001, Combined treatments for phobic anxiety disorders, 81, 10.1037/10415-004 · doi:10.1037/10415-004
- Simon, 2002, Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorder, Journal of Affective Disorders, 69, 201, 10.1016/S0165-0327(01)00359-7 · DOI
- Song, 2003, Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses, BMJ, 326, 472, 10.1136/bmj.326.7387.472 · DOI · Paper page
- Taylor, 2000, Understanding and Treating Panic Disorder
- Telch, 1994, A. Combined pharmacological and psychological tretment of panic disorder: Current status and future directions., 177
- Toni, 2000, A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants, Pharmacopsychiatry, 33, 121, 10.1055/s-2000-11221 · DOI · Paper page
- Balkom, 1996, Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia, Journal of Nervous and Mental Disease, 184, 133, 10.1097/00005053-199602000-00015 · DOI
- Watanabe, 2005, Combined psychotherapy plus benzodiazepines for panic disorder with or without agoraphobia [Protocol], Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005335 · DOI
- Weissman, 1997, The cross-national epidemiology of panic disorder, Archives of General Psychiatry, 54, 305, 10.1001/archpsyc.1997.01830160021003 · DOI · Paper page
- Westra, 1998, Cognitive behavioural therapy and pharmacotherapy: complementary or contradictory approaches to the treatment of anxiety?, Clinical Psychology Review, 18, 307, 10.1016/S0272-7358(97)00084-6 · DOI
Cited by
The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses
Hofmann, S. G., Asnaani, A., Vonk, I. J. J., Sawyer, A. T., & Fang, A. (2012) · Cognitive Therapy and Research · doi:10.1007/s10608-012-9476-1 · Cited by 3,445
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“, psychological [IV] (Schmidt and Keough, 2010) and combination [I (M)] (Furukawa et al., 2007; Watanabe et al., 2007) interventions are effective in the acute treatment of patients with panic disorder.”
BackgroundInfluentialCuijpers, P., Sijbrandij, M., Koole, S. L., Andersson, G., Beekman, A. T., & Reynolds, C. F. (2014) · World Psychiatry · doi:10.1002/wps.20089 · Cited by 424
Huhn, M., Tardy, M., Spineli, L. M., Kissling, W., Förstl, H., Pitschel-Walz, G., Leucht, C., Samara, M., Dold, M., Davis, J. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.112 · Cited by 333
Browning, M., Holmes, E. A., & Harmer, C. J. (2010) · Cognitive, Affective, & Behavioral Neuroscience · doi:10.3758/cabn.10.1.8 · Cited by 247
(2015) · PubMed · Cited by 229
Arch, J. J., & Craske, M. G. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.05.001 · Cited by 208
Bergström, J., Andersson, G., Ljótsson, B., Rück, C., Andréewitch, S., Karlsson, A., Carlbring, P., Andersson, E., & Lindefors, N. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-54 · Cited by 202
“Combining CBT with SSRI does not seem to lead to better treatment response than CBT alone [6].”
Anxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
Pompoli, A., Furukawa, T. A., Imai, H., Tajika, A., Efthimiou, O., & Salanti, G. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011004.pub2 · Cited by 142
Self-citationNaturopathic care for anxiety: a randomized controlled trial ISRCTN78958974
Cooley, K., Szczurko, O., Perri, D., Mills, E. J., Bernhardt, B., Zhou, Q., & Seely, D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006628 · Cited by 114
A systematic appraisal of allegiance effect in randomized controlled trials of psychotherapy
Dragioti, E., Dimoliatis, I., Fountoulakis, K. N., & Evangelou, E. (2015) · Annals of General Psychiatry · doi:10.1186/s12991-015-0063-1 · Cited by 91
Dowlati, Y., Herrmann, N., Swardfager, W. L., Reim, E. K., & Lanctôt, K. L. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005500205 · Cited by 79
Psychobehavioral therapy for epilepsy
Tang, V., Michaelis, R., & Kwan, P. (2014) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.12.004 · Cited by 76
Evidence-based pharmacotherapy of panic disorder: an update
Batelaan, N. M., Van Balkom, A. J. L. M., & Stein, D. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000800 · Cited by 67
“The incremental efficacy of combined psychotherapy (most often CBT) and antidepressant treatment was investigated in a Cochrane review including 21 trials in panic disorder (Furukawa et al. 2007).”
BackgroundMethodInfluentialSundermann, B., Bode, J., Lueken, U., Westphal, D., Gerlach, A. L., Straube, B., Wittchen, H.-U., Ströhle, A., Wittmann, A., Konrad, C., et al. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00099 · Cited by 46
Browning, M., Grol, M., Ly, V., Goodwin, G. M., Holmes, E. A., & Harmer, C. J. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.159 · Cited by 42
Horst, F., Den Oudsten, B., Zijlstra, W., de Jongh, A., Lobbestael, J., & De Vries, J. (2017) · Frontiers in Psychology · doi:10.3389/fpsyg.2017.01409 · Cited by 38
“Several controlled treatment effect studies have shown that cognitive behavioral therapy (CBT), particularly interoceptive exposure, is the most effective intervention for PD (Barlow et al., 1989, 2000; Öst et al., 2004; Furukawa et al., 2007).”
Moylan, S., Staples, J., Ward, S. A., Rogerson, J., Stein, D. J., & Berk, M. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822d0012 · Cited by 34
Elsas, S. M., Gregory, W. L., White, G., Navarro, G., Salinsky, M. C., & Andrews, D. J. (2011) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2011.09.030 · Cited by 33
“Another Cochrane review concludes on the basis of 21 clinical trials, which compared CBT with pharmacotherapy to pharmacotherapy alone, that CBT is effective for panic disorder [47].”
BackgroundSvensson, M., Nilsson, T., Perrin, S., Johansson, H., Viborg, G., Falkenström, F., & Sandell, R. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000511469 · Cited by 17
Metadata
- Authors
- Furukawa, T. A., Watanabe, N., & Churchill, R.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2007-01-24
- Volume
- 2010
- Issue
- 1
- Pages
- CD004364-CD004364
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1821129526
- Cited by
- 195
- References
- 23
- FWCI
- 12.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.